Cyclerion Therapeutics, Inc. (CYCN) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CYCN currently has 3.93M outstanding shares. with significant dilution risk as 5.33M authorized shares could dilute existing holders by 135.9%. The company has significantly diluted shareholders by 74.67% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 12, 2025 |
10-Q filing | 3.9M shares outstanding |
3.9M | 5.3M |
| Aug 05, 2025 |
10-Q filing | 3.1M shares outstanding |
3.1M | 6.2M |
| May 06, 2025 |
10-Q filing | 3.2M shares outstanding |
3.2M | 6.1M |
| May 06, 2025 |
S-3 filing: The filing is an S-3 registration statement for the offer and sale of up to 499,998 shares of common stock by selling stockholders. |
2.5M | 6.7M |
| Mar 04, 2025 |
10-K filing | 2.5M shares outstanding |
2.5M | 6.2M |
| Feb 04, 2025 |
S-3 filing: This S-3 filing indicates a potential offering of common stock, preferred stock, warrants, and units for an aggregate public offering price not exceeding $25,000,000. |
2.1M | 6.6M |
| Nov 14, 2024 |
10-Q filing | 2.5M shares outstanding |
2.5M | 1.5M |
| Aug 07, 2024 |
10-Q filing | 2.5M shares outstanding |
2.5M | 1.6M |
| May 07, 2024 |
10-Q filing | 2.5M shares outstanding |
2.5M | 1.6M |
| Mar 05, 2024 |
10-K filing | 2.7M shares outstanding |
2.7M | 1.4M |
| Nov 13, 2023 |
10-Q filing | 2.4M shares outstanding |
2.4M | 1.6M |
| Jul 28, 2023 |
10-Q filing | 2.3M shares outstanding |
2.3M | 1.8M |
| May 25, 2023 |
Stock Split
8-K filing: Cyclerion Therapeutics, Inc. issued 225,000 shares of Common Stock and 351,037 shares of Series A Preferred Stock to Peter M. Hecht, Ph.D. at a price of $8.68 per share, consummating the Purchase Agreement. ($5.0M proceeds) |
2.2M | 1.9M |
| May 12, 2023 |
10-Q filing | 43.5M shares outstanding |
44M | 38M |
| Mar 22, 2023 |
10-K filing | 43.5M shares outstanding |
43M | 38M |
| Nov 03, 2022 |
10-Q filing | 43.5M shares outstanding |
43M | 38M |
| Aug 09, 2022 |
10-Q filing | 43.5M shares outstanding |
43M | 38M |
| May 04, 2022 |
10-Q filing | 43.4M shares outstanding |
43M | 38M |
| Feb 24, 2022 |
10-K filing | 43.4M shares outstanding |
43M | 38M |
| Nov 09, 2021 |
10-Q filing | 43.3M shares outstanding |
43M | 38M |
| Jul 29, 2021 |
10-Q filing | 43.3M shares outstanding |
43M | 38M |
| Jun 23, 2021 |
S-3/A filing: This S-3/A filing registers 5,735,988 shares of common stock for sale by selling stockholders. |
34M | 47M |
| Jun 16, 2021 |
S-3 filing: This prospectus relates to the offer and sale from time to time by the selling stockholders identified in the section entitled "Selling Stockholders" of up to an aggregate of 5,735,988 shares of our common stock. |
34M | 47M |
| Jun 04, 2021 |
8-K filing: Cyclerion Therapeutics, Inc. entered into a Common Stock Purchase Agreement with seven investors for the private placement of 5,735,988 shares of its common stock at a purchase price of $3.12 per share, or $3.28 per share with respect to Peter Hecht, Ph.D., Chief Executive Officer of Cyclerion. |
34M | 41M |
| Apr 30, 2021 |
10-Q filing | 34.1M shares outstanding |
34M | 41M |
| Feb 25, 2021 |
10-K filing | 34.1M shares outstanding |
34M | 41M |
| Nov 05, 2020 |
10-Q filing | 34.0M shares outstanding |
34M | 42M |
| Aug 07, 2020 |
S-3 filing: This S-3 filing registers 6,062,500 shares of common stock for sale by selling stockholders. |
34M | 42M |
| Aug 03, 2020 |
10-Q filing | 33.9M shares outstanding |
34M | 36M |
| Jul 30, 2020 |
S-3/A filing: This S-3/A filing registers an indeterminate number of common stock, preferred stock, debt securities, warrants, and/or units with an aggregate initial offering price not to exceed $150,000,000. |
27M | 42M |
| Jul 24, 2020 |
S-3 filing: The filing is an S-3 registration statement for Cyclerion Therapeutics, Inc., covering common stock, preferred stock, debt securities, warrants, and units, with a total proposed amount of $150,000,000. The securities may be offered from time to time. |
27M | 650K |
| Mar 12, 2020 |
10-K filing | 27.8M shares outstanding |
28M | 0 |